The HPV Vaccine at 20. Years: A Rare Case in Which We Can Truly Prevent Cancer – The Remaining Barriers

What makes cervical cancer special is how clearly its cause is known. There are more than 200 types of HPV; only a small subset are cancer-causing (oncogenic). In particular, HPV 16 and 18 types account for most cases of cervical cancer — and all current vaccines target these two types.

A vaccine working in the laboratory is one thing; seeing it prevent cancer in real populations is something else entirely. The real-world evidence accumulated in recent years has exceeded even expectations.

In the shadow of these successes, an enormous tragedy continues — and its distribution is unjust.

In 2020, the World Health Organization set an unprecedented goal: to eliminate a cancer — cervical cancer — as a global public health problem. Elimination is defined as reducing the annual incidence of cervical cancer to below 4 per 100.000 women.

One of the biggest practical barriers was that the vaccine generally required two or three doses — particularly in countries with limited healthcare infrastructure, completing all doses poses a major logistical challenge. A development in 2022 changed the game.

For many years, the HPV vaccine was seen as "a vaccine that protects girls from cervical cancer." Science has shown, however, that the picture is much broader: HPV triggers not only cervical cancer, but many other cancers too.

With such strong evidence, why do thousands of women still die from this preventable cancer? Because even the best vaccine does not work unless it goes into an arm. Vaccination rates remain below target in much of the world.

Vaccine hesitancy is another important reason for coverage gaps. Understanding it — and responding with empathy, without blame — is integral to prevention efforts. Most hesitant parents are not acting in bad faith; they are families who want to protect their children but are confused.

The HPV vaccine's 20 years are one of the most beautiful stories modern medicine can tell: we discovered that a virus causes a cancer, developed a vaccine against that virus, and now — in real populations, with real data — we are watching that cancer fade away. Seeing zero deaths from cervical cancer among young women vaccinated early in England is not an abstract statistic; it means mothers who continue living, children growing up, and lives saved. This is the power not of treating cancer, but of preventing it from the outset — and nothing in oncology is more valuable. Yet the victory is not complete. Unless the vaccine goes into an arm, even the most brilliant science remains on paper. Coverage is still low in much of the world, inequalities are deep, and unfounded fears take their toll. The task for the coming years is not to invent a new vaccine — it is to deliver this extraordinary tool we already have to every girl and every boy in every country. Eliminating cervical cancer is no longer a question of "Is it possible?"; it is a question of "Will we do it?" The answer lies neither in the laboratory nor in the vaccine vial, but in information, access, and our sense of responsibility toward one another.

This article is intended for preventive health and information; it is not individual medical advice, a diagnosis, or a treatment recommendation. The effectiveness and safety data presented are based on observational and epidemiological findings available at the publication dates of the cited sources; although real-world studies (including Falcaro and colleagues) show strong associations, individual outcomes may vary. The safety of the HPV vaccine is supported by more than 500 million doses worldwide and over 20 years of follow-up; claims that the vaccine causes infertility or autoimmune diseases have no scientific basis. Vaccination decisions should be assessed together with a qualified physician (a pediatrician, family physician, or relevant specialist), according to personal health status and age; vaccination schedules and "catch-up" programs vary by country. This article aims to provide evidence-based, empathetic information rather than judge individuals experiencing vaccine hesitancy. Cervical cancer screening should continue as recommended, even in vaccinated individuals. All data were verified against The Lancet, Nature Medicine, WHO, GLOBOCAN, and relevant primary sources; the article contains no direct quotations.